drugset / Trial / NCT06178614
A Study of JNJ-87890387 for Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).
Timeline
- Start
- 2023-12-14
- Primary completion
- 2027-03-16
- Completion
- 2029-02-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JNJ-87890387 | Unknown | — | — |